Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline and Merck. Now, it's ready to make good on its promise.
India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.
Rotavirus vaccines RotaTeq and Rotarix from Merck and GlaxoSmithKline, respectively, have seen uptake grow over the past several years. And with good reason, a new study shows: As the vaccines have become more widespread, the number of children hospitalized for rotavirus-related diarrhea has plunged.
Software developed by researchers at the University of Pittsburgh and Johns Hopkins University has helped the Republic of Benin in West Africa deliver more vaccines to children most in need, according to a new study.
The U.S. childhood immunization schedule is overwhelmingly made up of injectables. Yet in among the vaccines for measles, mumps and other diseases are two orally delivered products--GlaxoSmithKline's and Merck's rotavirus vaccines. The rarity of oral vaccines means providers have less experience delivering them, but does this mean there are more errors?
Merck's rotavirus vaccine RotaTeq has faced close scrutiny since winning FDA approval in 2006, with authorities monitoring whether it shares side effects with a similar Wyeth product that was pulled from the market. Now a FDA-funded study has shown RotaTeq is linked to the side effect, but the benefits outweigh the risks.
A U.S. Centers for Disease Control and Prevention team has found a significant decrease in the number of rotavirus-related hospitalizations with routine use of GlaxoSmithKline ($GSK) and Merck's ($MRK) rotavirus vaccines in older age groups.
Norovirus has replaced rotavirus as the most common cause of acute infectious gastroenteritis in children in the U.S., a testament to the success of GlaxoSmithKline and Merck vaccines in stopping the spread of rotavirus. Development of a shot for norovirus is lagging behind, though.
Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.
British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.